Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 821 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Genotype Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Smokers' Response to Nicotine Dependence Genotyping

NCT01780038
View directory record Official record
Conditions
Cigarette Smoking, Nicotine Dependence
Interventions
Receipt of Genetic Results, No results given
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 18, 2026, 3:47 PM EDT
Completed Not applicable Interventional Results available

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

NCT02880293
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
melphalan, fludarabine, thiotepa, Cyclophosphamide, Mesna, Mycophenolate Mofetil, Filgrastim, Tacrolimus
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 18, 2026, 3:47 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

NCT02486406
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin, Ombitasvir mini tablet, Paritaprevir mini tablet, Ritonavir mini tablet, Dasabuvir mini tablet, Ribavirin solution
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 18, 2026, 3:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

RH Genotype Matched RBC Transfusions

NCT04156893
View directory record Official record
Conditions
Sickle Cells Disease
Interventions
Red cell units that are genotype matched at the RHD and RHCE loci
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 18, 2026, 3:47 PM EDT
Terminated No phase listed Observational

Study Evaluating Genotypes Using Lucentis

NCT00474695
View directory record Official record
Conditions
Age-Related Maculopathy
Interventions
Lucentis
Drug
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Santa Barbara, California • Denver, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Oct 18, 2026, 3:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ethical, Legal, and Social Issues Substudy in Relation to the GTEx Project

NCT02887339
View directory record Official record
Conditions
Standard Training, Online Training
Interventions
Training Website, Control
Other
Lead sponsor
Temple University
Other
Eligibility
Not listed
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 18, 2026, 3:47 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study

NCT07146412
View directory record Official record
Conditions
Cognitive Impairment, Alzheimer Blood Biomarkers, Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Interventions
Multimodal Lifestyle Intervention
Behavioral
Lead sponsor
HudsonAlpha Institute for Biotechnology
Other
Eligibility
65 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 3:47 PM EDT
Terminated Phase 3 Interventional Results available

Muscadine Plus (MPX) In Men With Prostate Cancer

NCT03535675
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Muscadine Plus, Placebos
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Duarte, California • La Jolla, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 18, 2026, 3:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Role of Polyunsaturated Fatty Acids (PUFA)-Gene Interactions in Heath Disparities

NCT02962128
View directory record Official record
Conditions
Fatty Acid-Gene Interactions
Interventions
High Linoleic Acid (LA) Diet, Low Linoleic Acid (LA) Diet
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 18, 2026, 3:47 PM EDT
Completed Phase 2 Interventional

A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

NCT05630066
View directory record Official record
Conditions
Angelman Syndrome
Interventions
Alogabat
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 18, 2026, 3:47 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men

NCT02816879
View directory record Official record
Conditions
Anal Carcinoma, HIV Infection, Human Papillomavirus Infection
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Palm Springs, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 18, 2026, 3:47 PM EDT
Active, not recruiting No phase listed Observational

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care

NCT02279004
View directory record Official record
Conditions
NSCLC, Melanoma
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 18, 2026, 3:47 PM EDT
Completed No phase listed Observational

Congenital Transmission of Lineages I and II of Trypanosoma Cruzi

NCT01787968
View directory record Official record
Conditions
Chagas Disease
Interventions
Not listed
Lead sponsor
Tulane University School of Public Health and Tropical Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
28,348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Oct 18, 2026, 3:47 PM EDT
Completed Phase 2 Interventional

Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

NCT00491543
View directory record Official record
Conditions
Diabetes, Coronary Artery Disease
Interventions
ALT-2074
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 18, 2026, 3:47 PM EDT
Terminated Phase 1 Interventional

Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

NCT00277758
View directory record Official record
Conditions
Hepatitis C
Interventions
Interleukin 2, Ribavirin, Pegylated Interferon Alpha, Inteleukin-2, Ribavirin + Pegylated interferon-alpha
Biological · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2008 · Synced Oct 18, 2026, 3:47 PM EDT
Completed No phase listed Observational

Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome

NCT01705925
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Not listed
Lead sponsor
Pediatrix
Other
Eligibility
Up to 20 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 18, 2026, 3:47 PM EDT
Recruiting No phase listed Observational

Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene

NCT01145196
View directory record Official record
Conditions
Genotype, Retinal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 3:47 PM EDT
Completed Not applicable Interventional

Haptoglobin Phenotype, Vitamin E and High-density Lipoprotein (HDL) Function in Type 1 Diabetes

NCT01098994
View directory record Official record
Conditions
Type 1 Diabetes, Heart Disease
Interventions
Vitamin E, Dummy pills
Dietary Supplement · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
30 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 18, 2026, 3:47 PM EDT
Completed Not applicable Interventional

Breastfeeding Self-Management for Nipple and Breast Pain

NCT03392675
View directory record Official record
Conditions
Breastfeeding, Breast Pain
Interventions
Self-monitoring of BF and intervention
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Farmington, Connecticut • Manchester, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 18, 2026, 3:47 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Phenotype, Genotype & Biomarkers in ALS and Related Disorders

NCT02327845
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Progressive Muscular Atrophy, Multisystem Proteinopathy
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
Not listed
Enrollment
708 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2031
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 18, 2026, 3:47 PM EDT
Active, not recruiting Phase 2 Interventional

A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

NCT07157254
View directory record Official record
Conditions
Angelman Syndrome
Interventions
No intervention, GTX-102
Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
1 Year to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 3:47 PM EDT
Completed No phase listed Observational

Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

NCT00437060
View directory record Official record
Conditions
Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia, Cognitive Side Effects of Cancer Therapy, Long-Term Effects Secondary to Cancer Therapy in Children, Neurotoxicity Syndrome, Psychological Impact of Cancer, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
Cognitive Assessment, Diffusion Tensor Imaging, Laboratory Biomarker Analysis, Pharmacological Study, Psychosocial Assessment and Care
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
102
States / cities
Birmingham, Alabama • Downey, California • Long Beach, California + 83 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 18, 2026, 3:47 PM EDT
Completed No phase listed Observational

DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701

NCT01057459
View directory record Official record
Conditions
Lymphoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 18, 2026, 3:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genetic Basis for Variation in the Renal Elimination of Metformin

NCT00187720
View directory record Official record
Conditions
Other Conditions That May Be A Focus of Clinical Attention
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 18, 2026, 3:47 PM EDT